Drugs / SOF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02120300 | Apr 2014 → Aug 2015 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02120300 ↗ |
| Route | Oral | “400 mg tablet administered orally once daily” NCT02120300 ↗ |